Chemesis International Inc. Provides Update on Rapid Dose
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis International Inc. Provides Update on Rapid Dose
After completing installation, permitting and the testing phase, Chemesis has begun accepting orders of
QuickStripTM Oral Thin Strips
September 4, 2019
Vancouver, BC – Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or
“Chemesis”), is proud to announce its subsidiary, Natural Ventures, has completed the installation,
permitting, and testing phase of its Quick Strip™ oral thin strip production equipment. The Company has
completed the previously announced commercialization strategy, and has begun accepting orders for
QuickStrip for immediate distribution across Puerto Rico and the United States.
Since receiving Gold Vendor Status from Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) Chemesis
has continued to work diligently to ensure the Quick Strip go to market strategy is done effectively and
efficiently. The Company expects to see a consistent increase in revenue as consumers move to a more
Quick, Convenient, Precise, and Discrete™ method of consumption.
“Our partnership with RDT brings an incre dible amount of potential growth for Chemesis,” said Chief
Executive Officer of Chemesis, Edgar Montero. “The partnership gives Chemesis access to a large market
of consumers that are looking for alternatives that provide a No Smoke, No Smell, No Stigma™
administration of THC or CBD.”
On Behalf of The Board of Directors
Edgar Montero
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated U.S. Multi -State operator with International
operations in Puerto Rico and Colombia.
The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it
enters new markets and is committed to differentiate itself by deploying resources in markets with major
opportunities. The Company operates a portfolio of brands that cater to a wide community of cannabis
consumers, with focus on quality and consistency.
Chemesis has facilities in both Puerto Rico and California and is in the process of constructing a GMP
certified facility in Colo mbia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft 2 of
cultivation, and 35,000 ft 2 of manufacturing floor space. The Company is positioned to win additional
licenses in highly competitive merit-based US states and will expand its footprint to ensure it maintains a
first mover advantage.
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
GreenSpiritRX
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. is a publicly -traded Canadian life sciences company that provides
innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT
offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to
clinical research and product development for the healthcare manufacturing industry, including
nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn -
key Manage d Strip Service Program which enables RDT’s QuickStrip™ proprietary drug delivery
technology to be licensed by select partners. RDT’s service -based annuity contracts drive recurring
revenue which enables rapid expansion into emerging markets — generating value for consumers and
shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at
multiple consumer segments and future market needs — including humans, animals and plants.
For more information, visit: www.rapid-dose.com
For inquiries please contact:
Ian Fodie, CFO Ali Mahdavi, Managing Director
Rapid Dose Therapeutics Corp. Spinnaker Capital Markets Inc.
[email protected] [email protected]
Office (416) 477-1052 Office (416) 962-3300
Social Media
RapidDoseTherapeutics.linkedin
RapidDoseTherapeutics.twitter
RapidDoseTherapeutics.facebook
QuickStrip.instagram
Forward-Looking Information: This news release contains "forward -looking information" within the meaning of
applicable securities laws relating to statements regarding the Company's busi ness, products and future of the
Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that
the expectations reflected in the forward -looking information are reasonable, there can be no assurance that su ch
expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward -looking
information. Such forward -looking statements are subject to risks and uncertainties that may cause actual results,
performance and developments t o differ materially from those contemplated by these statements depending on,
among other things, the risks that the Company's products and plan will vary from those stated in this news release
and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company
expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking
information in this news release. Although the Company believes that the expectations r eflected in the forward -
looking information are reasonable, there can be no assurance that such expectations will prove to be correct and
makes no reference to profitability based on sales reported. The statements in this news release are made as of the
date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release